Funding for this research was provided by:
National Cancer Institute (R01CA17094605, R01CA12472311)
National Institute of Diabetes and Digestive and Kidney Diseases (DK11757601, R01DK11183402)
Received: 5 March 2019
Accepted: 30 April 2019
First Online: 20 May 2019
Change Date: 4 September 2019
Change Type: Correction
Change Details: Following publication of the original article , the authors found an error in Figure 3. The middle panel of Figure 3a was inadvertently duplicated.
Availability of data and materials
: All data generated or analyzed during this study are included in this published article [and its additional information files].
: The study involved apheresis samples from de-identified patients. It was deemed exempt by the Institutional Review Board at University of Miami. All animal studies were done according to protocols approved by the International Animal Care and Use Committee (IACUC) at University of Miami, FL.
: All authors have seen and consented to publication of this work. No other consent is applicable.
: These authors disclose the following: Ashok Saluja: The University of Minnesota has a patent for Minnelide, which has been licensed to Minneamrita Therapeutics, LLC. A.S. is the co-founder and the Chief Scientific Officer of this company. This relationship is managed by the University of Miami. Sulagna Banerjee is a compensated consultant with Minneamrita Therapeutics LLC and this relationship is managed by the University of Miami. The remaining authors disclose no competing interests.